The information contained in this section of the site is intended for US health care professionals and specialty pharmacy representatives only. Click “OK” if you are a health care professional or specialty pharmacy representative.
The HEMLIBRA Co-pay Program may help eligible commercially insured patients who have been prescribed HEMLIBRA with their medicine co-pays.
Eligible commercially insured patients can save $15,000 per year in medicine costs. They pay as little as $5 per co-pay.
Patients may owe more than $5 depending on how the health insurance plan applies manufacturer co-pay assistance to out-of-pocket costs.
If a patient is not eligible for the HEMLIBRA Co-pay Program, there may be other options for co-pay assistance. Call (866) HEMLIBRA (866-436-5427) or visit HEMLIBRA.com/access to learn more.
HEMLIBRA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A with or without factor VIII inhibitors.
Important Safety Information
Boxed WARNING: THROMBOTIC MICROANGIOPATHY and THROMBOEMBOLISM
Cases of thrombotic microangiopathy and thrombotic events were reported when on average a cumulative amount of >100 U/kg/24 hours of activated prothrombin complex concentrate (aPCC) was administered for 24 hours or more to patients receiving HEMLIBRA prophylaxis. Monitor for the development of thrombotic microangiopathy and thrombotic events if aPCC is administered. Discontinue aPCC and suspend dosing of HEMLIBRA if symptoms occur.
Warnings and Precautions
Most Common Adverse Reactions
The most common adverse reactions (incidence rate ≥ 10%) were injection site reactions and headache, and arthralgia.
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.
Please see the HEMLIBRA full Prescribing Information for additional Important Safety Information, including Boxed WARNING.